Lyrica (pregabalin) is not a narcotic. It works through a completely different mechanism than opioids and does not bind to opioid receptors in the brain. However, Lyrica is a controlled substance, classified as Schedule V by the DEA, which is the lowest level of controlled substance in the United States. That distinction matters because many people use “narcotic” and “controlled substance” interchangeably, but they mean very different things.
Why Lyrica Is Not a Narcotic
Narcotics, in the pharmacological sense, refer to opioid drugs that act on opioid receptors to relieve pain and produce sedation. Think morphine, oxycodone, or fentanyl. Lyrica doesn’t work this way at all. Instead, it binds to a specific part of calcium channels on nerve cells (called alpha-2-delta subunits), which reduces the amount of calcium flowing into those cells. Less calcium means the nerves release fewer signaling chemicals, including ones involved in transmitting pain signals and ramping up excitability in the nervous system.
Despite being originally designed to mimic GABA (a calming brain chemical), pregabalin doesn’t actually activate GABA receptors either. Its pain-relieving and anti-anxiety effects come entirely from dampening overactive nerve signaling through those calcium channels. This mechanism is fundamentally different from how any narcotic works.
Why It Is a Controlled Substance
When the DEA placed pregabalin into Schedule V in 2005, it made three formal findings: pregabalin has a low potential for abuse compared to drugs in Schedule IV, it has accepted medical uses, and abuse may lead to limited physical or psychological dependence. Schedule V is the least restrictive controlled category. For context, Schedule II includes drugs like oxycodone and fentanyl, while Schedule IV includes medications like benzodiazepines and sleep aids.
The controlled status means your pharmacy tracks Lyrica prescriptions and your doctor writes them with certain documentation requirements, but it does not carry the same prescribing restrictions as higher-schedule medications. You won’t encounter the same refill limitations or monitoring protocols that apply to opioids.
The Abuse and Dependence Risk
Lyrica’s Schedule V classification reflects a real, if relatively low, potential for misuse. At higher-than-prescribed doses, some people experience sedation and euphoria. Pregabalin’s faster absorption and quicker onset of action compared to gabapentin (a related medication) contribute to this risk. Case reports describe individuals taking many times the prescribed dose to chase euphoric effects, with one documented case involving a person consuming 8.4 grams daily, far beyond the normal therapeutic range.
Dependence can develop with regular use, even at prescribed doses. People who become dependent on pregabalin typically experience tolerance (needing higher doses for the same effect), cravings, and withdrawal symptoms when stopping. Withdrawal can include palpitations, tremors, irritability, insomnia, anxiety, and in severe cases of high-dose misuse, auditory hallucinations. Those with a history of substance use disorders face a higher risk of misusing pregabalin.
How to Stop Lyrica Safely
You should not stop Lyrica abruptly. The FDA-approved prescribing information states that pregabalin should be tapered gradually over a minimum of one week. Stopping suddenly can cause insomnia, nausea, headache, and diarrhea. If you take Lyrica for seizures, abrupt discontinuation can increase seizure frequency. Your prescriber will typically set up a gradual dose reduction schedule based on how much you’ve been taking and for how long.
What Lyrica Is Prescribed For
The FDA has approved Lyrica for several conditions related to nerve pain and seizures. The standard (immediate-release) formulation is approved for neuropathic pain from diabetic nerve damage, pain following shingles (postherpetic neuralgia), fibromyalgia, and as an add-on treatment for partial onset seizures in adults. The extended-release version (Lyrica CR) is approved only for diabetic nerve pain and post-shingles pain.
In practice, doctors also prescribe Lyrica off-label for generalized anxiety disorder and other chronic pain conditions, though these uses don’t carry formal FDA approval.
Regulations Outside the United States
Lyrica’s legal status varies by country, and some jurisdictions treat it more strictly than the U.S. does. The United Kingdom reclassified pregabalin (along with gabapentin) as a Class C controlled drug in April 2019, placing it under Schedule 3 of the Misuse of Drugs Regulations. This subjects it to stricter prescription documentation, record-keeping, and supply requirements than it faces in the U.S. The move was driven by rising reports of pregabalin misuse, addiction, and diversion in the UK. Several other countries in Europe and the Middle East have similarly tightened regulations around pregabalin in recent years.
If you’re traveling internationally with a Lyrica prescription, it’s worth checking the specific regulations in your destination country, since the level of documentation required to carry it across borders varies significantly.